The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)

Stopped early · Phase 3

Conditions studied: Constipation Predominant, Irritable Bowel Syndrome (IBS-C)

In brief

Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.

Key facts

Study ID

NCT00171431

Run by

Novartis Pharmaceuticals

People needed

20

Starts

2004-11-01

Expected to finish

2006-05-01

Last updated by the study team

2012-04-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female 18 and older
• IBS-C patients diagnosed on the basis of Rome II criteria
• Ability to comply with the requirements of the entire study

You may not qualify if…

• Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.
• Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.
• Evidence of cathartic colon or a history of laxative use, that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.